menu

JÖRG DEBATIN TO CHAIR THE SUPERVISORY BOARD OF HUMMINGBIRD DIAGNOSTICS GMBH International healthcare leader strengthens miRNA experts

HEIDELBERG, BOSTON, October 9, 2018 – Hummingbird Diagnostics GmbH today announced that Prof. Dr. med. Jörg Debatin is appointed Chairman of the Supervisory Board with immediate effect.

The former Vice President and Chief Technology Officer of GE Healthcare and CEO of Amedes AG directed the University Hospital Hamburg-Eppendorf for 8 years as its Medical Director and CEO.

He started his professional career as a diagnostic radiologist at the University Hospitals of Duke, Stanford and Zürich (Switzerland). In 1999, he was appointed Professor of Diagnostic Radiology at the University of Essen. Debatin has studied medicine at the University of Heidelberg and holds an Executive MBA from the University of St. Gallen.

As a renowned international healthcare leader, he has extensive academic, clinical, and entrepreneurial experience in the fields of medical diagnostics and disease management as well as the implementation of innovative technologies.

Thus, Prof. Debatin ideally augments the wide-ranging expertise of the Hummingbird Supervisory Board. Leading scientists, industrial managers and experienced investors support the company in expanding its portfolio of products and applications.

“At Hummingbird, we are delighted to have Jörg Debatin on board, a globally renowned healthcare leader,” says Jochen Kohlhaas, CEO of Hummingbird Diagnostics GmbH. “His longstanding experience is invaluable for our future corporate development.”

“I am very happy to support Hummingbird Diagnostics in navigating upcoming challenges”, Prof. Debatin remarks. “Using blood-based biomarkers for measuring the immune responses to disease holds immense promise for screening, symptom-based diagnostics, disease-specific prognosis and monitoring of patient-centered therapies.”

Hummingbird Diagnostics GmbH

Hummingbird Diagnostics GmbH develops patient-friendly diagnostics for early disease detection based on miRNA biomarkers from blood, in particular for malignant tumors. In addition, the company is working on life-accompanying tests for healthy aging.

For further information please contact:

Hummingbird Diagnostics GmbH

Im Neuenheimer Feld 583
D-69120 Heidelberg
phone +49 (0)6221 91433-10
fax +49 (0)6221 91433-12info@hb-dx.com www.hummingbird-diagnostics.com

GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER